Data for this analysis were sourced from the Danish High Risk and Resilience Study. Participants were identified through the Danish Civil Registration System and Danish Psychiatric Central Research Register.
This study recruited individuals aged 12-30 years who had first-degree relatives with BD I or II and those with no family history of mental illness.
Researchers examined the effect of neuropeptides orexin-A, ghrelin, and neuropeptide Y on hypersomnia and hyperphagia. Both symptoms are more common in people with bipolar disorder.
Using a quantitative application of Rothman’s theoretical framework of causation, the researchers sought to investigate if manic and anxiety symptoms contribute to suicidal ideation in individuals with bipolar disorder during a depressive state.
Schizophrenia and bipolar I patients experience cognitive decline through adulthood, although the nature of this decline varies across disorders and cognitive functions.
Study data published in the Journal of Affective Disorders describe the impact of dispositional mindfulness on depressive symptoms and quality of life in patients with bipolar disorder.
In both trials, BXCL501 demonstrated statistically significant, rapid and durable improvements vs placebo across multiple agitation scales.
